Here are the S-3 shelf registrations from Dermata Therapeutics, Inc. Warrant (DRMAW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow DRMAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRMAW filings page.
Dermata Therapeutics, Inc. proposes a shelf offering registering up to $100,000,000 of common stock, preferred stock, warrants, debt securities, subscription rights and units, to be offered from time to time.
The prospectus describes the company’s strategic shift from Rx dermatology to direct-to-consumer and B2B cosmetic skincare products using its Bioneedle ingredient derived from Spongilla lacustris, plans to launch a Foundational Treatment in mid-2026, and continued exploration of topical botulinum toxin applications. It discloses recent ATM sales of 824,283 shares for approximately $2.0 million, pro forma shares outstanding of 4,022,143 as of May 21, 2026, a public float of $3,955,179.64, and recent net losses of $1.8 million for Q1 2026 and $7.6 million for 2025.
Dermata Therapeutics, Inc. is registering up to 6,207,730 shares of common stock for resale by existing investors under a Form S-3 registration statement. These shares include 1,484,312 common shares plus shares issuable upon exercise of 537,750 pre-funded warrants, 2,022,062 Series C warrants, 2,022,062 Series D warrants, and 141,544 placement agent warrants, all issued in a December 29, 2025 private placement. Dermata will not receive proceeds from stockholder resales but would receive cash only if the warrants are exercised, which it plans to use for working capital and general corporate purposes.
The company describes a major strategic shift from prescription dermatology to over-the-counter, science-backed products built on its Spongilla technology, with an initial once-weekly topical acne kit targeted for launch in mid-2026. Dermata also notes a 1-for-10 reverse stock split effective August 1, 2025 and highlights Nasdaq listings for its common stock and public warrants under the symbols “DRMA” and “DRMAW.”